title: ["Morning type" and "evening type" in activated osteoarthritis. Analysis and practice-related conclusions of an open, multicenter study with ibuprofen].
abstract: 3,672 patients with activated osteoarthritis were treated for 20 days with daily doses of 1,800 to 2,400 mg ibuprofen (Anco). Patients experiencing the greatest pain in the morning (6-12 a.m.) or in the evening (3-9 p.m.) were grouped together as morning type and evening type, respectively and submitted to subgroup analysis. An explorative, stepwise logistic regression with the variable morning type/evening type revealed the dominant factors which, in the order given, represent the most accurate criteria for characterizing the two types to be: pain at rest at the start of the trial, localization of arthritis, and occupation. The consistency of the pain-time profile throughout the 20-day treatment period further showed that these two subgroups actually do exist and can be differentiated. A consideration of benefit/risk ratio revealed no differences between the groups and the overall population, although an advantage vis-a-vis pretreatment was observed. A therapeutic recommendation that can be derived from the findings is that, depending upon the pain-time profile, a higher doses should be given in the morning and evening, respectively, and that no medication need be given during periods with little or no pain.
authors.forename: J
authors.initials: J
authors.lastname: Moerchel
authors.forename: K F
authors.initials: KF
authors.lastname: Karrasch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010003:Osteoarthritis / Q000145:classification / Q000188:drug therapy*
chemical_list: D007052:Ibuprofen
vernacular_title: "Morgentyp" und "Abendtyp" bei aktivierter Osteoarthrose. Analysen und praxisbezogene Schlussfolgerungen einer offenen, multizentrischen Studie mit Ibuprofen.